Compare Hilton Hotels Corporation Common Stock (HLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.1 (market cap $70.82B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Hilton Hotels Corporation Common Stock pays a 0.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hilton Hotels Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| HLT | XBI | |
|---|---|---|
Market Cap | $70.82B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $350.22 | $164.28 |
52-Week Low | $256.75 | $86.92 |
Enterprise Value | $83.83B | — |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.16, up 3.91% over 24 hours, with a bullish analyst consensus of 57% buy ratings and a $352 price target. Recent earnings have consistently beaten estimates, with Q2 2026 EPS at $2.29 matching expectations. The stock shows bearish technical signals but strong fundamentals, including revenue growth to $12.04B in 2025 and a net income margin of 12.69%. However, rising debt levels and a high P/E ratio of 46.21 pose valuation concerns.
The outlook for HLT is positive due to robust travel demand and a growing hotel pipeline, though premium valuation and increasing debt require caution. Investment opportunity lies in sustained earnings growth and capital returns, while risks include economic sensitivity and labor disputes, as highlighted by ongoing strikes and soft Q3 guidance affecting investor sentiment.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
